人民卫生出版社系列期刊
ISSN 2096-2738 CN 11-9370/R

中国科技核心期刊(中国科技论文统计源期刊)
2020《中国学术期刊影响因子年报》统计源期刊

新发传染病电子杂志 ›› 2022, Vol. 7 ›› Issue (3): 22-26.doi: 10.19871/j.cnki.xfcrbzz.2022.03.005

• 论著 • 上一篇    下一篇

新型冠状病毒德尔塔和奥密克戎变异株感染患者的临床特征分析

张影1, 李晓鹤1, 陈凤2, 袁静1   

  1. 1. 深圳市第三人民医院感染科,广东 深圳 518112;
    2. 中山大学附属第七医院消化医学中心,广东 深圳 518107
  • 收稿日期:2022-05-21 出版日期:2022-07-31 发布日期:2022-09-08
  • 通讯作者: 袁静,Email:13500054798@139.com
  • 基金资助:
    1.国家重点研发计划(2021YFC2301803); 2.广东省高水平临床重点专科建设项目(深圳市配套建设经费)(SZGSP11)

Clinical characteristics of patients infected with SARS-CoV-2 Delta and Omicron variants

Zhang Ying1, Li Xiaohe1, Chen Feng2, Yuan Jing1   

  1. 1. Department of Infectious Diseases, Shenzhen Third People's Hospital, Guangdong Shenzhen 518000, China;
    2. Digestive Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Guangdong Shenzhen 518107,China
  • Received:2022-05-21 Online:2022-07-31 Published:2022-09-08

摘要: 目的 比较新型冠状病毒(SARS-CoV-2)德尔塔(Delta)和奥密克戎(Omicron)变异株感染患者的临床特征,为新型冠状病毒肺炎的防治提供参考。方法 采用回顾性研究方法,收集2021年6月11日至2021年11月8日深圳市第三人民医院收治的23例新型冠状病毒Delta变异株(Delta组),以及2022年2月21日至2022年3月9日收治的34例Omicron变异株感染患者(Omicron组)的临床资料,比较分析不同变异株感染患者的临床症状、SARS-CoV-2疫苗接种情况、实验室检测结果及胸部CT影像学特征等。结果 新型冠状病毒Delta和Omicron变异株感染者中,男性35例(61.4%),以青中年为主(56例,98.2%)。两组患者的临床表现主要为咳嗽、咽喉痛和发热。临床分型以轻型为主,Omicron组的轻型患者显著多于Delta组(χ2=11.797,P<0.05),未见重型患者。Omicron组接种SARS-CoV-2疫苗加强针的人数多于Delta组(χ2=12.853, P<0.05)。90.9%(50例)患者在发病时距离末次接种疫苗的时间在1个月以上,但两组患者在发病时距末次接种疫苗的时间比较差异无统计学意义(χ2=3.079, P>0.05)。实验室检查结果中,Delta组患者的IL-6水平较高,而血清K和LDH的水平较低(均P<0.05)。两组患者在入院时的病毒核酸Ct值中位数均低于20,Omicron组患者在病程第3、7、14、21天的核酸Ct值均显著高于Delta组(均P<0.05),在病程第14天和第21天的病毒核酸转阴病例数显著多于Delta组(均P<0.05),且其病毒核酸阳性持续时间和住院时间也显著短于Delta组(均P<0.05)。比较两组患者的抗体水平发现,Omicron组和Delta组患者在入院时的IgG阳性率分别为64.7%和34.8%,Omicron组的IgM和IgG的中位数水平均显著高于Delta组(均P<0.05);病程第7天时,Omicron组的IgG阳性率为93.7%,Delta组的IgG阳性率为75.0%,两组的IgM和IgG水平的比较无显著性差异(均P>0.05)。结论 Delta和Omicron变异株感染者均具有较强的传染性,Omicron变异株感染者的病毒核酸转阴更快,二者可能对现有的SARS-CoV-2疫苗有一定的免疫逃逸。

关键词: 新型冠状病毒, 变异株, 德尔塔, 奥密克戎, 临床特征

Abstract: Objective To investigate the clinical characteristics and laboratory tests of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variant infections cases, and to provide reference for the prevention and treatment of SARS-CoV-2. Methods A retrospective study was conducted to collect the clinical data of 23 cases of SARS-CoV-2 Delta variant admitted to Shenzhen Third People's Hospital from June 11, 2021 to November 8, 2021, and 34 patients with Omicron variant admitted from February 21, 2022 to March 9, 2022. We compared and analyzed the clinical symptoms, vaccination, laboratory test results, and chest CT imaging features of patients infected with different variants. Result s Among patients infected with the Delta and Omicron variants, 35 cases (61.4%) were males, and 56 cases (98.2%) were young and middle-aged. The main clinical manifestations were cough, sore throat and fever, clinical staging was predominantly mild (χ2=11.797, P<0.05), and no severe cases. Comparing the two groups of patients receiving COVID-19 vaccine vaccination, it was found that the number of patients in Omicron group received booster shots of COVID-19 vaccine than Delta group (χ2=12.853, P<0.05). The time from the last vaccination to the onset was more than 1 month in 90.9%(50 cases) patients, but there was no significant difference between the two groups (χ2=3.079, P>0.05). In comparison of laboratory test results between the two groups, IL6 levels were higher while serum K and LDH levels were lower in the Delta group, with statistically significant differences (all P<0.05). The median Ct value of viral nucleic acid in both groups at admission were lower than 20, and the nucleic acid Ct values in the Omicron group at day 3, 7, 14, and 21 were significantly higher than that in the Delta group (all P<0.05), the number of viral nucleic acid negative cases at day 14 and 21 was significantly higher than those in the Delta group (all P<0.05). The positive duration of viral nucleic acid and hospital stay were also significantly shorter than those in Delta group (all P<0.05).In comparison of antibody levels between the two groups, the IgG positive rate of Omicron and Delta group at admission was 64.7% and 34.8%, respectively, the median level of IgM and IgG in Omicron group was significantly higher than that in Delta group (all P<0.05). On day 7, the IgG positive rate of Omicron and Delta group was 93.7% and 75.0%, respectively, and there was no significant difference in the comparison of IgM and IgG between the two groups (all P>0.05). Conclusion Patients infected with Delta and Omicron variants both have strong infectivity, and the Omicron variant infected patients with the virus's nucleic acid turned negative more quickly. Both may have certain immune escape against the existing COVID-19 vaccines.

Key words: Severe acute respiratory syndrome coronavirus 2, Variant, Delta, Omicron, Clinical characteristics